Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

AN2 Therapeutics, Inc. ANTX NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
53/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$7.75
+160.1%

AN2 Therapeutics, Inc. (ANTX) is a Biotechnology company in the Healthcare sector, currently trading at $2.98. It has a SharesGrow Score of 51/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is ANTX = $8 (+160.1% upside).

Valuation: ANTX trades at a trailing Price-to-Earnings (P/E) of -2.8 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.23.

Net income is $35M (loss), growing at -2%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $53M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 6.87 (strong liquidity). Debt-to-assets is 0%. Total assets: $62M.

Analyst outlook: 5 / 8 analysts rate ANTX as buy (63%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 73/100 (Pass), Income ?/100 (Fail).

$7.75
▲ 160.07% Upside
Average Price Target
Based on 8 Wall Street analysts offering 12-month price targets for AN2 Therapeutics, Inc., the average price target is $7.75, with a high forecast of $22.00, and a low forecast of $2.00.
Highest Price Target
$22.00
Average Price Target
$7.75
Lowest Price Target
$2.00

ANTX SharesGrow Score Overview

63/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 73/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ANTX

✓
VALUE Pass
100/100
ANTX trades at a trailing Price-to-Earnings (P/E) of -2.8 (S&P 500 average ~25). Forward PEG 0.23 — Peter Lynch undervalued (≤1.0). Trailing PEG 0.79. Analyst consensus target is $8, implying +168.5% from the current price $3. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
ANTX: +0%/yr revenue is, -2%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet ANTX: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 6.87 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
ANTX: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
73/100
Analyst outlook: 5 / 8 analysts rate ANTX as buy (63%). Analyst consensus target is $8 (+168.5% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1-6.91
Volume556.08K
Avg Volume (30D)1.41M
Market Cap$81.66M
Beta (1Y)-1.32
Share Statistics
EPS (TTM)-1.16
Shares Outstanding$30.22M
IPO Date2022-03-25
Employees22
CEOEric E. Easom
Financial Highlights & Ratios
EBITDA$-38.11M
Net Income$-35.17M
Operating Income$-38.11M
Total Cash$58M
Net Debt$-19.94M
Total Assets$61.95M
Price / Earnings (P/E)-2.6
Analyst Forecast
1Y Price Target$3.50
Target High$22.00
Target Low$2.00
Upside+17.4%
Rating ConsensusBuy
Analysts Covering8
Buy 63% Hold 38% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS0373261058

Price Chart

Track all markets on TradingView
ANTX
AN2 Therapeutics, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
1.00 52WK RANGE 6.91

People Also View

PHVS
PHVS
Pharvaris N.V.
$28.68
+2.87%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$27.32
+0.59%
 ELYM
ELYM
Eliem Therapeutics, Inc.
$5.11
-0.97%
 RZLT
RZLT
Rezolute, Inc.
$3.56
-1.36%
 MOLN
MOLN
Molecular Partners AG
$4.14
-1.66%
 ADAG
ADAG
Adagene Inc.
$3.81
-0.78%
 PEPG
PEPG
PepGen Inc.
$1.69
+0.59%
 PMVP
PMVP
PMV Pharmaceuticals, Inc.
$1.47
+8.89%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message